Hsu et al., "An open-label, prospective pilot clinical study of
denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis," The Journal of Clinical Endocrinology & Metabolism, vol.
Denosumab, a monoclonal antibody to the RANK ligand, has recently been used in a few cases and has been shown to decrease tumor burden size, reduce pain, resolve associated neurologic symptoms, and show evidence of radiographic healing [9-11].
Denosumab reduces bone resorption, increases bone mineral density (BMD), and reduces fracture risk [1].
Denosumab is a monoclonal antibody against the receptor activator of nuclear factor-[kappa][beta] ligand (RANKL), a cytokine that is essential for the formation, function, and survival of osteoclasts [6].
The patient subsequently began cycle 2 of cisplatin, doxorubicin, and cytoxan which was completed prior to discharge with a plan to initiate
denosumab as an outpatient.
Denosumab is a human monoclonal antibody that inhibits normal and tumor associated RANKL [13-15].
More recently, RANK-Ligand inhibitors (
denosumab) have also been used to reduce the risk of skeletal-related events in patients who have advanced cancers with bone metastases.
16 December 2015 - US-based biotechnology company Amgen (NASDAQ: AMGN) has entered into a definitive agreement with UK-based drugmaker GSK to reacquire all of its remaining rights to Prolia (
denosumab), Xgeva (
denosumab) and Vectibix (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world, the company said.
* 2 studies that explore the use of zoledronic acid or
denosumab in women with breast cancer undergoing adjuvant therapy with an aromatase inhibitor
Denosumab is a fully-human, immunoglobulin G1 (IgG2) mAb against RANKL that is in Phase III of development for RA patients with active, erosive bone disease.
CHICAGO -- Postmenopausal women on
denosumab for 8 years straight showed a continued nearlinear increase in bone mineral density at the lumbar spine as well as persistent reduction of bone turnover markers and a sustained low incidence of new vertebral and nonvertebral firactures in the ongoing FREEDOM open-label extension study.